Please assess the completion status of the following clinical trial:

Trial Title: Reduced Intensity AlloSCT in(CML) With Persistent Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: Patient must be less than 30 years of age.~* Consent: Patient or the patient's legally authorized guardian must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects), and must sign an informed consent in accordance with the institutional policies approved by the U.S. Department of Health and Human Services.~* Organ Function: Patient must have adequate organ function as below Adequate renal function defined as:Serum creatinine 1.5 x normal, or Creatinine clearance or radioisotope GFR \> 40 ml/min/m2 or \>60 ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range~* Adequate liver function defined as:Total bilirubin \< 2.5 x normal; or SGOT (AST) or SGPT (ALT) \< 5.0 x normal~* Adequate cardiac function defined as:~  * Shortening fraction of \>25% by echocardiogram, or~ * Ejection fraction of \>40% by radionuclide angiogram or echocardiogram~* Adequate pulmonary function defined as:~  -DLCO \>40% by pulmonary function test For children who are uncooperative, no evidence of dyspnea at rest,no exercise intolerance, and a pulse oximetry \>94% in room air.~* Disease Status~  * Patients with CML with either of the following:~ * Patients in 1st or 2nd chronic phase~ * Patients in 1st or 2nd accelerated phase~Exclusion Criteria:~* Patient in blast crisis~* Patient in 3rd or greater chronic phase~* Patient in 3rd or greater accelerated phase~  * women that are pregnant are ineligible

- Gender: ALL
- Minimum Age: None
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Matched Family Donor (Type: EXPERIMENTAL): Matched Family Donor
- Unrelated Donor (Type: EXPERIMENTAL): Unrelated Donor Transplant/ Cord Blood Transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).